{"id":"https://openalex.org/W2944766449","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07","title":"Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups","display_name":"Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups","publication_year":2019,"publication_date":"2019-02-15","ids":{"openalex":"https://openalex.org/W2944766449","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07","mag":"2944766449"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs18-p3-08-07","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077763512","display_name":"Jeremy Meyer Force","orcid":"https://orcid.org/0000-0002-3326-2715","observed_orcids":["https://orcid.org/0000-0002-3326-2715"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Force","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036584093","display_name":"Jennifer Kay Plichta","orcid":"https://orcid.org/0000-0002-7411-0558","observed_orcids":["https://orcid.org/0000-0002-7411-0558"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Plichta","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072025170","display_name":"Ilona Stashko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I Stashko","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059225709","display_name":"Gretchen Genevieve Kimmick","orcid":"https://orcid.org/0000-0001-7096-9624","observed_orcids":["https://orcid.org/0000-0001-7096-9624"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G Kimmick","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069078449","display_name":"Kelly E. Westbrook","orcid":"https://orcid.org/0000-0001-9640-1076","observed_orcids":["https://orcid.org/0000-0001-9640-1076"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K Westbrook","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013516632","display_name":"Sarah LeNoir Sammons","orcid":"https://orcid.org/0000-0003-2589-9422","observed_orcids":["https://orcid.org/0000-0003-2589-9422"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Sammons","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S Hwang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Hwang","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061721402","display_name":"Terry Hyslop","orcid":"https://orcid.org/0000-0002-3930-8876","observed_orcids":["https://orcid.org/0000-0002-3930-8876"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T Hyslop","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000753119","display_name":"Noah D. Kauff","orcid":"https://orcid.org/0000-0001-7242-6156","observed_orcids":["https://orcid.org/0000-0001-7242-6156"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N Kauff","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045623927","display_name":"Edgardo R. Parrilla Castellar","orcid":"https://orcid.org/0000-0002-5721-2763","observed_orcids":["https://orcid.org/0000-0002-5721-2763"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E Castellar","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112382666","display_name":"Shalima S. Nair","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Nair","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029754146","display_name":"Kent J. Weinhold","orcid":"https://orcid.org/0000-0003-4876-6737","observed_orcids":["https://orcid.org/0000-0003-4876-6737"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K Weinhold","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S Davis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Davis","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034422841","display_name":"Afshin Mashadi-Hossein","orcid":"https://orcid.org/0000-0002-2337-2195","observed_orcids":["https://orcid.org/0000-0002-2337-2195"]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A Mashadi-Hossein","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029019474","display_name":"HA Brauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"HA Brauer","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066125634","display_name":"P. Kelly Marcom","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099129","display_name":"Nanostring Technologies (United States)","ror":"https://ror.org/00xzdzk88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210099129"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"PK Marcom","raw_affiliation_strings":["Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","Nanostring Technologies, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC; Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Nanostring Technologies, Seattle, WA","institution_ids":["https://openalex.org/I4210099129"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"4_Supplement","first_page":"P3","last_page":"08"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brca1","display_name":"BRCA1","score":0.8980000019073486},{"id":"https://openalex.org/keywords/brca2","display_name":"BRCA2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.9470000267028809},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.7590000033378601},{"id":"https://openalex.org/keywords/gene-expression-signatures","display_name":"gene expression signatures","score":0.703000009059906},{"id":"https://openalex.org/keywords/esr1","display_name":"ESR1","score":0.5799999833106995},{"id":"https://openalex.org/keywords/pgr","display_name":"PGR","score":0.8429999947547913},{"id":"https://openalex.org/keywords/stromal-markers","display_name":"stromal markers","score":0.6340000033378601},{"id":"https://openalex.org/keywords/proinflammatory-chemokines","display_name":"inflammatory chemokines","score":0.8190000057220459},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.6980000138282776},{"id":"https://openalex.org/keywords/hormone-receptor-status","display_name":"hormone receptor status","score":0.44999998807907104}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.7558690309524536},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7318620085716248},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.6439297199249268},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6213908195495605},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5639969110488892},{"id":"https://openalex.org/C109825262","wikidata":"https://www.wikidata.org/wiki/Q1139164","display_name":"Germline","level":3,"score":0.552699089050293},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4920808672904968},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4280080795288086},{"id":"https://openalex.org/C13514818","wikidata":"https://www.wikidata.org/wiki/Q5552256","display_name":"Germline mutation","level":4,"score":0.4153793156147003},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.29852294921875},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.2960604429244995},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20570525527000427},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.15107914805412292}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs18-p3-08-07","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-p3-08-07","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2890903658","https://openalex.org/W3043889711","https://openalex.org/W4283706803","https://openalex.org/W6901935752","https://openalex.org/W6902210413","https://openalex.org/W6939701184","https://openalex.org/W6902193491","https://openalex.org/W6958849521","https://openalex.org/W2091423117","https://openalex.org/W6958556432"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"BRCA":[2,27,71,90,491],"mutated":[3,492],"(BRCA+)":[4],"breast":[5,44,65,85,128,336,421],"cancers":[6,45,66,86,407],"are":[7],"expected":[8],"to":[9,26,42,55,61,111,123,302,328,348,366],"have":[10,339,356],"increased":[11,343],"activation":[12],"of":[13,51,172,215,232,309,376,419,497],"Homologous":[14],"Recombination":[15],"Deficiency":[16],"(HRD)":[17],"and":[18,39,68,73,88,95,109,144,163,192,223,236,342,353,359,382,399,404,414],"altered":[19],"DNA":[20],"damage":[21],"repair":[22],"pathways":[23],"when":[24,326,364],"compared":[25,166,327,347,365],"wildtype":[28],"(BRCA-).":[29],"To":[30],"better":[31],"understand":[32],"differences":[33,320,363,489],"in":[34,155,159,280,291,312,321,393,490],"these":[35,390,420],"populations,":[36],"biological":[37,426,486],"patterns":[38,427],"immune":[40],"responses":[41],"BRCA+":[43,76,113,137,242,286,335,449],"were":[46,251,256,275],"evaluated.":[47],"The":[48,115,136,240,373,424],"primary":[49],"aim":[50],"our":[52],"study":[53],"was":[54,101,121,151,267],"use":[56],"novel":[57],"gene":[58,319,361],"expression":[59,214,231,362],"tools":[60,438],"assess":[62],"early":[63,82,333,447],"stage":[64,83,110,334,448],"with":[67,87,167,259,277,379,385],"without":[69,89],"germline":[70],"mutations,":[72],"within":[74],"distinct":[75,245,370],"subgroups.":[77],"Methods:":[78],"We":[79],"identified":[80,428],"124":[81],"untreated":[84],"mutations":[91],"(n":[92],"=":[93,131,134],"62":[94],"62,":[96],"respectively).":[97],"Our":[98],"BRCA-":[99,133,169,329,349,367],"group":[100,138],"matched":[102],"by":[103],"hormone":[104,394],"receptor":[105,395],"(HR)":[106],"status,":[107],"age,":[108],"the":[112,161,168,303,313,498],"group.":[114],"NanoString":[116],"Breast":[117,502],"Cancer":[118,503,514],"360":[119],"panel":[120,315],"applied":[122],"RNA":[124],"isolated":[125],"from":[126],"80":[127],"tumors":[129,165,211,228,255,274,287,325,338,355,378,384],"(BRCA+":[130],"39;":[132],"41).":[135],"had":[139,212,229,244,288],"a":[140,145,152,260,289,306,409],"BRCA1+":[141,162,210,254,324,352,377],"subgroup":[142,147],"(n=17)":[143],"BRCA2+":[146,164,227,271,273,322,354,383],"(n=22).":[148],"Results:":[149],"There":[150],"significant":[153,269],"increase":[154,279],"two":[156,241],"BC360":[157,304,314],"signatures":[158,487],"both":[160,357],"population:":[170],"Prosigna\u2122Risk":[171],"Recurrence":[173],"(ROR)":[174],"score":[175],"[BRCA1+:":[176,194,296],"HR:":[177,185,195,203],"1.142":[178],"(95%":[179,187,197,205],"CI":[180,188,198,206],"1.019,":[181],"1.279),":[182],"p=0.02;":[183,201],"BRCA2+:":[184,202,298],"1.321":[186],"1.190,":[189],"1.466),":[190],"p<0.001]":[191],"HRD":[193,344],"3.576":[196],"2.174,":[199],"5.880),":[200],"1.801":[204],"1.142,":[207],"2.840),":[208],"p<0.001].":[209],"lower":[213,230],"ESR1":[216],"[p=0.03],":[217],"PGR":[218],"[p=0.02],":[219],"ER":[220],"signaling":[221],"[p<0.001],":[222,263],"differentiation":[224],"[p=0.005];":[225],"while":[226],"stroma":[233],"markers":[234],"[p=0.02]":[235],"inflammatory":[237],"chemokines":[238],"[p=0.001].":[239],"subgroups":[243,493],"molecular":[246],"subtype":[247,262,283,294],"correlation":[248,295,375],"trends":[249],"that":[250,439],"highly":[252],"significant.":[253],"positively":[257],"associated":[258,276,406],"basal":[261],"whereas":[264],"this":[265],"association":[266],"not":[268],"for":[270,411,417,446],"tumors.":[272,330,350],"an":[278],"luminal":[281,292],"B":[282],"[p=0.05].":[284],"All":[285],"decrease":[290],"A":[293],"p<0.001;":[297],"p=0.002].":[299],"In":[300,332],"addition":[301],"signatures,":[305],"differential":[307],"analysis":[308],"all":[310],"genes":[311],"revealed":[316],"more":[317],"single":[318,360],"than":[323],"Conclusions:":[331],"cancer,":[337],"higher":[340],"ROR":[341],"signature":[345,358],"scores":[346],"Furthermore,":[351],"tumors,":[368],"indicating":[369],"subgroup-related":[371],"biology.":[372],"greater":[374],"basal-like":[380],"biology":[381,388],"aggressive":[386],"hormonal":[387],"confirms":[389],"trends.":[391],"Distinctions":[392],"signaling,":[396],"DNA-damage":[397],"pathways,":[398],"microenvironment/inflammatory":[400],"features":[401],"between":[402],"BRCA1":[403],"BRCA2":[405],"suggest":[408],"need":[410],"different":[412],"prevention":[413],"therapeutic":[415],"strategies":[416],"each":[418],"cancer":[422],"subtypes.":[423],"unique":[425],"here":[429],"should":[430],"be":[431,441],"further":[432],"evaluated":[433],"as":[434],"predictive":[435],"or":[436],"prognostic":[437],"could":[440],"translated":[442],"into":[443],"clinical":[444],"care":[445],"patients.":[450],"Citation":[451],"Format:":[452],"Force":[453],"J,":[454,456],"Plichta":[455],"Stashko":[457],"I,":[458],"Kimmick":[459],"G,":[460],"Westbrook":[461],"K,":[462,476],"Sammons":[463],"S,":[464,466,474,478],"Hwang":[465],"Hyslop":[467],"T,":[468],"Kauff":[469],"N,":[470],"Castellar":[471],"E,":[472],"Nair":[473],"Weinhold":[475],"Davis":[477],"Mashadi-Hossein":[479],"A,":[480],"Brauer":[481],"HA,":[482],"Marcom":[483],"PK.":[484],"Distinct":[485],"describe":[488],"[abstract].":[494],"In:":[495],"Proceedings":[496],"2018":[499,505],"San":[500,508],"Antonio":[501],"Symposium;":[504],"Dec":[506],"4-8;":[507],"Antonio,":[509],"TX.":[510],"Philadelphia":[511],"(PA):":[512],"AACR;":[513],"Res":[515],"2019;79(4":[516],"Suppl):Abstract":[517],"nr":[518],"P3-08-07.":[519]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2019-05-16T00:00:00"}